OnabotulinumtoxinA (Botox) appears to increase the activity of brain regions involved in sensation and processing of urinary urgency in female patients with neurogenic overactive bladder, says Rose Khavari, MD.
Among 321 scheduled telemedicine visits for patients with neurogenic bladder, the compliance rate was 91%.
Analyses with patients stratified into three groups by age showed that an emulsified microdose desmopressin acetate nasal spray (Noctiva) consistently extended the first uninterrupted sleep period in a clinically meaningful manner for patients of all ages.
“Unless there’s a contraindication, they have to try medications. ‘I don’t feel like taking it’ is not failing a medication,” says one urologist.
Attorneys will scour for online ‘dirt’ to use in a lawsuit, writes Brianne Goodwin, JD, RN.
Modifier use without supporting documentation could be considered fraudulent, write Ray Painter, MD, and Mark Painter.
Data from a recent study also indicate that overactive bladder patients discontinue pharmacotherapy long-term despite chronic symptoms.
Until now there has been no large, thorough investigation into the risk of clean intermittent catheterization in patients undergoing repeat injections of onabotulinumtoxinA.
"Concerns about scope of practice aside, there is no doubt that as the demand for urologic services increases and the number of practicing urologists decreases, we will need to find alternative ways to continue to see and treat our patients," writes Henry Rosevear, MD.